Article
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet (London, England) - 13 Jun 2020
Gutzmer Ralf, Stroyakovskiy Daniil, Gogas Helen, Robert Caroline, Lewis Karl, Protsenko Svetlana, Pereira Rodrigo P, Eigentler Thomas, Rutkowski Piotr, Demidov Lev, Manikhas Georgy Moiseevich, Yan Yibing, Huang Kuan-Chieh, Uyei Anne, McNally Virginia, McArthur Grant A, Ascierto Paolo A
Abstract excerpt
BACKGROUND: IMspire150 aimed to evaluate first-line combination treatment with BRAF plus MEK inhibitors and immune checkpoint therapy in BRAFV600 mutation-positive advanced or metastatic melanoma. METHODS: IMspire150 was a randomised, double-blind, placebo-controlled phase 3 study done at 112 institutes in 20 countries. Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.